Celgene Corporation provided earnings guidance for the fourth quarter and full year ended December 31, 2015 and earnings guidance for the year 2016. Fourth quarter of 2015 net product sales are expected to be approximately $2,540 million. Adjusted diluted EPS is expected to be approximately $4.71, a 27% year-over-year increase, and reflects $0.14 dilution associated with the Receptos Inc. transaction. GAAP diluted EPS is expected to be in the range of $1.89 to $1.99, and reflects $0.40 dilution associated with the Receptos Inc. transaction. GAAP diluted EPS is expected to be in the range of $1.89 to $1.99, and reflects $0.40 dilution associated with the Receptos Inc. transaction. For the fourth quarter of 2015 adjusted diluted EPS is expected to be approximately $1.18, including a $0.07 impact from a $70 million milestone achieved by OncoMed Pharmaceuticals Inc. during the quarter. GAAP diluted EPS is expected to be in the range of $0.63 to $0.73.

For the year 2015, total net product sales is expected to be approximately $9,160 million, up 21% year-over-year.

In 2016, net product sales are expected to be approximately $10.5 billion to $11.0 billion, a 17% increase year-over-year, based on the mid-point of the range. The negative impact of foreign exchange on net product sales is expected to be approximately $120 million in 2016. Adjusted diluted earnings per share is expected to be in the range of $5.50 to $5.70, a 19% increase year-over-year, based on the mid-point of the range.